You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients

Article info

Article menu

Download PDFPDF

Research Article
Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients

Authors

  • Christina Jensen Biomarkers and Research, Nordic Bioscience Herlev Hovedgade 205-207 2730 Herlev Denmark Biotech Research and Innovation Centre (BRIC), University of Copenhagen Ole Maaløes Vej 5 2200 Copenhagen N Denmark PubMed articlesGoogle scholar articles
  • Daniel Hargbøl Madsen Center for Cancer Immune Therapy, Department of Haematology and Department of OncologyHerlev Hospital, University of Copenhagen Herlev Ringvej 75 2730 Herlev Denmark PubMed articlesGoogle scholar articles
  • Morten Hansen Center for Cancer Immune Therapy, Department of Haematology and Department of OncologyHerlev Hospital, University of Copenhagen Herlev Ringvej 75 2730 Herlev Denmark PubMed articlesGoogle scholar articles
  • Henrik Schmidt Department of OncologyAarhus University Hospital Nørrebrogade 44 8000 Aarhus C Denmark PubMed articlesGoogle scholar articles
  • Inge Marie Svane Center for Cancer Immune Therapy, Department of Haematology and Department of OncologyHerlev Hospital, University of Copenhagen Herlev Ringvej 75 2730 Herlev Denmark PubMed articlesGoogle scholar articles
  • Morten Asser Karsdal Biomarkers and Research, Nordic Bioscience Herlev Hovedgade 205-207 2730 Herlev Denmark PubMed articlesGoogle scholar articles
  • Nicholas Willumsen Biomarkers and Research, Nordic Bioscience Herlev Hovedgade 205-207 2730 Herlev Denmark PubMed articlesGoogle scholar articles

Citation

Jensen C, Madsen DH, Hansen M, et al
Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients
Journal for ImmunoTherapy of Cancer 2018;6:152. doi: 10.1186/s40425-018-0474-z
Online issue publication 
February 10, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.